![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: STK4 |
Gene summary for STK4 |
![]() |
Gene information | Species | Human | Gene symbol | STK4 | Gene ID | 6789 |
Gene name | serine/threonine kinase 4 | |
Gene Alias | KRS2 | |
Cytomap | 20q13.12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q13043 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6789 | STK4 | LZE4T | Human | Esophagus | ESCC | 5.25e-16 | 5.59e-01 | 0.0811 |
6789 | STK4 | LZE7T | Human | Esophagus | ESCC | 2.22e-09 | 6.08e-01 | 0.0667 |
6789 | STK4 | LZE8T | Human | Esophagus | ESCC | 5.63e-03 | 2.89e-01 | 0.067 |
6789 | STK4 | LZE20T | Human | Esophagus | ESCC | 4.89e-12 | 3.59e-01 | 0.0662 |
6789 | STK4 | LZE22T | Human | Esophagus | ESCC | 2.23e-06 | 3.37e-01 | 0.068 |
6789 | STK4 | LZE24T | Human | Esophagus | ESCC | 6.84e-24 | 4.72e-01 | 0.0596 |
6789 | STK4 | LZE21T | Human | Esophagus | ESCC | 2.25e-03 | 2.22e-01 | 0.0655 |
6789 | STK4 | LZE6T | Human | Esophagus | ESCC | 5.05e-12 | 5.72e-01 | 0.0845 |
6789 | STK4 | P1T-E | Human | Esophagus | ESCC | 2.48e-10 | 5.64e-01 | 0.0875 |
6789 | STK4 | P2T-E | Human | Esophagus | ESCC | 9.80e-21 | 4.67e-01 | 0.1177 |
6789 | STK4 | P4T-E | Human | Esophagus | ESCC | 6.54e-24 | 4.24e-01 | 0.1323 |
6789 | STK4 | P5T-E | Human | Esophagus | ESCC | 1.19e-13 | 2.81e-01 | 0.1327 |
6789 | STK4 | P8T-E | Human | Esophagus | ESCC | 3.52e-19 | 4.45e-01 | 0.0889 |
6789 | STK4 | P9T-E | Human | Esophagus | ESCC | 4.90e-05 | 1.11e-01 | 0.1131 |
6789 | STK4 | P10T-E | Human | Esophagus | ESCC | 3.73e-46 | 7.30e-01 | 0.116 |
6789 | STK4 | P11T-E | Human | Esophagus | ESCC | 1.53e-07 | 4.12e-01 | 0.1426 |
6789 | STK4 | P12T-E | Human | Esophagus | ESCC | 1.02e-22 | 4.37e-01 | 0.1122 |
6789 | STK4 | P15T-E | Human | Esophagus | ESCC | 2.37e-30 | 5.18e-01 | 0.1149 |
6789 | STK4 | P16T-E | Human | Esophagus | ESCC | 2.90e-32 | 5.90e-01 | 0.1153 |
6789 | STK4 | P17T-E | Human | Esophagus | ESCC | 6.92e-11 | 3.23e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000189211 | Liver | HCC | embryonic placenta development | 50/7958 | 82/18723 | 5.62e-04 | 3.61e-03 | 50 |
GO:000189011 | Liver | HCC | placenta development | 81/7958 | 144/18723 | 5.91e-04 | 3.75e-03 | 81 |
GO:001081122 | Liver | HCC | positive regulation of cell-substrate adhesion | 70/7958 | 123/18723 | 8.74e-04 | 5.18e-03 | 70 |
GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:00459263 | Liver | HCC | negative regulation of growth | 129/7958 | 249/18723 | 1.81e-03 | 9.37e-03 | 129 |
GO:00061122 | Liver | HCC | energy reserve metabolic process | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
GO:0051262 | Liver | HCC | protein tetramerization | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
GO:003032311 | Liver | HCC | respiratory tube development | 95/7958 | 181/18723 | 4.15e-03 | 1.81e-02 | 95 |
GO:00018384 | Liver | HCC | embryonic epithelial tube formation | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
GO:009728421 | Liver | HCC | hepatocyte apoptotic process | 12/7958 | 16/18723 | 8.74e-03 | 3.40e-02 | 12 |
GO:003526421 | Liver | HCC | multicellular organism growth | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
GO:00721754 | Liver | HCC | epithelial tube formation | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
GO:003032411 | Liver | HCC | lung development | 91/7958 | 177/18723 | 1.01e-02 | 3.80e-02 | 91 |
GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
GO:00351484 | Liver | HCC | tube formation | 77/7958 | 148/18723 | 1.20e-02 | 4.39e-02 | 77 |
GO:00442641 | Liver | HCC | cellular polysaccharide metabolic process | 52/7958 | 96/18723 | 1.38e-02 | 4.91e-02 | 52 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa052232 | Liver | HCC | Non-small cell lung cancer | 46/4020 | 72/8465 | 3.61e-03 | 1.12e-02 | 6.22e-03 | 46 |
hsa040685 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa0522311 | Liver | HCC | Non-small cell lung cancer | 46/4020 | 72/8465 | 3.61e-03 | 1.12e-02 | 6.22e-03 | 46 |
hsa040688 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa052236 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa0406813 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0522315 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0406823 | Oral cavity | EOLP | FoxO signaling pathway | 29/1218 | 131/8465 | 1.05e-02 | 2.85e-02 | 1.68e-02 | 29 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0406833 | Oral cavity | EOLP | FoxO signaling pathway | 29/1218 | 131/8465 | 1.05e-02 | 2.85e-02 | 1.68e-02 | 29 |
hsa040687 | Prostate | BPH | FoxO signaling pathway | 54/1718 | 131/8465 | 3.05e-08 | 3.59e-07 | 2.22e-07 | 54 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK4 | SNV | Missense_Mutation | c.499N>C | p.Asp167His | p.D167H | Q13043 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
STK4 | SNV | Missense_Mutation | c.1340N>C | p.Arg447Thr | p.R447T | Q13043 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STK4 | SNV | Missense_Mutation | rs768691855 | c.1408N>T | p.Arg470Trp | p.R470W | Q13043 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STK4 | SNV | Missense_Mutation | c.499G>A | p.Asp167Asn | p.D167N | Q13043 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
STK4 | insertion | Frame_Shift_Ins | novel | c.945_946insCAAACATT | p.Asp316GlnfsTer31 | p.D316Qfs*31 | Q13043 | protein_coding | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |||
STK4 | insertion | In_Frame_Ins | novel | c.946_947insTGGCAGCTATAACATGTTCCCAAC | p.Asp316delinsValAlaAlaIleThrCysSerGlnHis | p.D316delinsVAAITCSQH | Q13043 | protein_coding | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |||
STK4 | SNV | Missense_Mutation | novel | c.970G>A | p.Glu324Lys | p.E324K | Q13043 | protein_coding | tolerated(0.11) | benign(0.15) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
STK4 | SNV | Missense_Mutation | c.535G>A | p.Ala179Thr | p.A179T | Q13043 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
STK4 | SNV | Missense_Mutation | novel | c.1364N>C | p.Met455Thr | p.M455T | Q13043 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
STK4 | SNV | Missense_Mutation | c.415N>C | p.Tyr139His | p.Y139H | Q13043 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A6-6648-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 252827426 | ||
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 178102336 | BOSUTINIB | |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 310264738 | CERDULATINIB | |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
Page: 1 |